Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Capital Expenditures (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Capital Expenditures for 7 consecutive years, with $31000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 24.0% year-over-year to $31000.0, compared with a TTM value of $77000.0 through Dec 2025, up 18.46%, and an annual FY2025 reading of $77000.0, up 18.46% over the prior year.
  • Capital Expenditures was $31000.0 for Q4 2025 at aTYR PHARMA, down from $37000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.4 million in Q2 2023 and bottomed at $8000.0 in Q2 2024.
  • Average Capital Expenditures over 5 years is $325789.5, with a median of $37000.0 recorded in 2025.
  • The sharpest move saw Capital Expenditures soared 6116.67% in 2022, then plummeted 99.67% in 2024.
  • Year by year, Capital Expenditures stood at $18000.0 in 2021, then skyrocketed by 6116.67% to $1.1 million in 2022, then crashed by 98.48% to $17000.0 in 2023, then surged by 47.06% to $25000.0 in 2024, then rose by 24.0% to $31000.0 in 2025.
  • Business Quant data shows Capital Expenditures for ATYR at $31000.0 in Q4 2025, $37000.0 in Q3 2025, and $9000.0 in Q2 2025.